Nucl Med Mol Imaging.  2018 Oct;52(5):325-326. 10.1007/s13139-018-0540-y.

Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma

• Chung JK
• Kim HW
• Youn H
• Cheon GJ

• KMID: 2422792
• DOI: http://doi.org/10.1007/s13139-018-0540-y

Abstract

Although radioiodine has been applied in thyroid diseases including carcinoma for over 70 years, it was only in 1996 that the basic molecular mechanism of iodine uptake was identified. Iodide is actively transported into the thyroid via a membrane glycoprotein known as sodium iodide symporter (NIS). NIS mediates radioiodine uptake into thyroid normal and cancer cells. The knowledge on NIS expression has provided scientific background to the empirical management of thyroid carcinoma. Based on recent studies of the NIS gene, this paper provides current clinical applications and future studies.

Keyword

Sodiumiodide symporter; NIS; Thyroid cancer; Gene therapy; Theranostics

MeSH Terms

Genetic Therapy
Humans
Iodine
Ion Transport*
Membrane Glycoproteins
Sodium Iodide*
Sodium*
Theranostic Nanomedicine
Thyroid Diseases
Thyroid Gland*
Thyroid Neoplasms*
Iodine
Membrane Glycoproteins
Sodium
Sodium Iodide